GlassScriptPhysician profile
Lawrence D Rosman
NPI 1063405652
$2,685.91
in general payments reported to CMS, 2019-2025
26 companies · $24.26 in 2025
The $24.26 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $580 · 2020: $676 · 2021: $594 · 2022: $720 · 2023: $92.55 · 2025: $24.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $92.55 · Education: $24.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $92.55 |
| Education | $24.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $379.03 | 2021-2023 | Unithroid |
| Lilly USA, LLC | $362.11 | 2019-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $298.10 | 2019-2022 | |
| Amgen INC. | $298.07 | 2019-2025 | Tepezza |
| Astrazeneca Pharmaceuticals LP | $227.96 | 2019-2020 | |
| Novo Nordisk INC | $216.28 | 2019-2023 | Wegovy, Saxenda |
| Abbvie INC. | $127.45 | 2020-2023 | Synthroid |
| Mannkind Corporation | $111.60 | 2019-2021 | |
| Dexcom, INC. | $85.46 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $79.88 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $58.93 | 2019 | |
| Becton, Dickinson and Company | $53.76 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $52.78 | 2022 | |
| Radius Health, INC. | $47.71 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $43.44 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.19 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $25.00 | 2021 | |
| Amarin Pharma, INC. | $22.92 | 2019 | |
| Alexion Pharmaceuticals, INC. | $22.73 | 2022 | |
| Bigfoot Biomedical INC | $22.22 | 2022 | |
| Ibsa Pharma INC. | $21.66 | 2020 | |
| Esperion Therapeutics, INC. | $18.75 | 2020 | |
| Vivus LLC | $18.48 | 2020 | |
| Horizon Therapeutics Plc | $17.85 | 2022 | |
| Senseonics, Incorporated | $17.00 | 2019 | |
| Pfizer INC. | $13.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Rosman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.